Evidence map›Paper›PMID 38567195›Full record

ArticleOpen forum infectious diseases2024

Prevalence of Chronic Pulmonary Aspergillosis in Two (2) Tuberculosis Treatment Clinics in Lagos, Nigeria: A Prospective Longitudinal Study.

Adeyinka A Davies, Abiola O Adekoya, Oluwaseyi J Balogun, Iriagbonse I Osaigbovo, Augustina Nwosu, Titilola Gbaja-Biamila, Olubunmi Osinupebi, Jean-Pierre Gangneux, Rita O Oladele

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Pooled it
  2. Article
  3. Performance of the LDBioMicrobiology spectrum · 2026
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Molecular identification and antifungal susceptibility testing ofAfrican journal of laboratory medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Adeyinka A DaviesDepartment of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.ORCID https://orcid.org/0000-0002-6849-1315
Abiola O AdekoyaDepartment of Radiology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.
Oluwaseyi J BalogunDepartment of Biomedical Engineering, University of Lagos, Lagos, Nigeria.
Iriagbonse I OsaigbovoMedical Mycology Society of Nigeria, Lagos, Nigeria.ORCID https://orcid.org/0000-0001-8111-0743
Augustina NwosuMedical Mycology Society of Nigeria, Lagos, Nigeria.
Titilola Gbaja-BiamilaClinical Sciences Division, Nigeria Institute of Medical Research, Yaba, Lagos, Nigeria.
Olubunmi OsinupebiDepartment of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.
Jean-Pierre GangneuxLaboratoire de Parasitologie et Mycologie, European Excellence Center in Medical Mycology, French National Reference Center for Chronic Aspergillosis, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Rita O OladeleMedical Mycology Society of Nigeria, Lagos, Nigeria.ORCID https://orcid.org/0000-0003-1488-3345
Olabisi Onabanjo University Teaching Hospital · NGUniversity of Lagos · NGInserm · FRLagos University Teaching Hospital · NGSaint Louis University · USUniversity of Benin · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic pulmonary aspergillosis (CPA) is an underrecognized but common complication of pulmonary tuberculosis. In Nigeria, a tuberculosis-endemic country, there is currently no provision to monitor the development of CPA in patients treated for tuberculosis. This study determined the prevalence and incidence of CPA in Lagos, Nigeria. Methods: A prospective longitudinal study of patients with previously managed tuberculosis was conducted between June 2021 and May 2022. The study cohorts were assessed at 3-month intervals, and the following were collected: sociodemographic data, chest radiographic findings, sputum samples for fungal culture, and venous blood samples for Results: Of the 141 patients recruited, 79 (56.0%) were in the retreatment and 62 (44.0%) in the posttreatment tuberculosis group. The median age (interquartile range) was 40 (30-52) years, with a male-to-female ratio of 1.1:1. Ninety-seven patients (69%) had a GeneXpert test done, of whom 63 (64.9%) were GeneXpert negative. Cough was the most common symptom, with 15 (11%) patients having hemoptysis. The rate of CPA increased steadily as the study progressed: 44 (31.2%) at commencement, 45 (34.9%) at 3 months, 49 (42.6%) at 6 months, and 51 (54.3%) at 9 months. Thus, the overall prevalence of CPA was 49.7%, and the incidence was 6.1%. Conclusions: CPA is common in Nigeria and its true burden may still be underestimated. Increased awareness of CPA as a posttuberculosis lung disease is advocated. Evaluation for CPA should be incorporated in patients' work-up for tuberculosis.

Indexed as

aspergillus IgGchronic pulmonary aspergillosislung diseaseNigeriapulmonary tuberculosis

Identifiers

PMID38567195
PMCPMC10986852
OpenAlexW4391898896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.